Molecular and genetic features of primary hyperparathyroidism in young patients

When primary hyperparathyroidism (PHPT) is diagnosed in a young patient in the absence of other clinical manifestations differential diagnosis between a sporadic form of PHPT and PHPT as the first manifestation of one of hereditary syndromes may be challenging. Diagnosis of sporadic or hereditary PHPT determines the extent of surgical intervention, a strategy for further observation and treatment, and the need for examination and treatment of first-degree relatives. 

Aim of the study — to determine genetic characteristics of PHPT with manifestation at a young age (<40 years old) with clinically sporadic PHPT and familial isolated hyperparathyroidism (FIHP).

Material and methods. 40 patients with manifestation of PHPT at the age younger than 40 years, 4 of which with FIHP, were included in the study. In 11 patients Sanger sequencing of MEN1 gene was performed (ABI 3130 Genetic Analyser, «Applied Biosystems», USA). 37 patients underwent next-generation sequencing (NGS) (Ion Torrent PGM, Thermo Fisher Scientific — Life Technologies, USA) using a panel of candidate genes (MEN1, CASR, CDC73, CDKN1A, CDKN1B, CDKN1C, CDKN2A, CDKN2C, CDKN2D). 

Results. In 3 (7,5%) patients (1 of which with FIHP) we revealed germline heterozygous mutations in MEN1 gene: in exon 9 p.D418N, exon 3 p.R176Q, intron 3 с.654+1G>A. In 4 (4/40, 10%) patients we revealed germline heterozygous mutations in CDC73 gene: 3 nonsense mutations in patients with parathyroid carcinoma — in exon 3 p.R91X, exon 6 p.Q166X, exon 7 p.R229X, and 1 missense mutation in a patient with parathyroid hyperplasia in exon 8 p.R263C. 

Conclusions. In the majority of cases (75%) PHPT in young patients without positive family history is sporadic. Search for germline mutations in the genes, leading to development of hereditary forms of PHPT (first of all in MEN1 and CDC73), is appropriate in young patients with positive family history, or when positive family history may be suspected, and in patients with parathyroid carcinoma. In the majority (75%) of FIHP cases search for other, probably yet unknown, genes is necessary.

1. Silverberg SJ. Primary Hyperparathyroidism. In: Rosen CJ, Editor. Primer On The Metabolic Bone Diseases And Disorders Of Mineral Metabolism. 8th Ed. Wiley-Blackwell; 2013. P. 543-552.

2. Мокрышева Н.Г., Рожинская Л.Я, Перетокина Е.В., и др. Анализ основных эпидемиологических характеристик первичного гиперпаратиреоза в России (по данным регистра). // Проблемы Эндокринологии. – 2012. – Т. 58 – №5 – С. 16—20. [Mokrysheva NG, Rozhinskaia Li, Peretokina Ev, et al. The Results Of Analysis Of The Major Epidemiological Characteristics Of Primary Hyperparathyroidism In Russia Based On The Registry Data. Probl Endokrinol (Mosk). 2012;58(5):16-20. (In Russ.)]. doi: 10.14341/Probl201258516-20.

3. Мокрышева Н.Г. Первичный гиперпаратиреоз. Эпидемиология, клиника, современные принципы диагностики и лечения: Дис. ... докт. мед. наук. – Москва; 2011. [Mokrysheva NG. Pervichnyi Giperparatireoz. Epidemiologiya, Klinika, Sovremennye Printsipy Diagnostiki I Lecheniya. [Dissertation]. Moscow; 2011. (In Russ).]. Доступно По: Http://Test.Vak.Ed.Gov.Ru/Common/Img/Uploaded/Files/Mokryshevang-0.Pdf. Ссылка Активна На 26.01.2016.

4. Giusti F, Cavalli L, Cavalli T, Brandi ML. Hereditary Hyperparathyroidism Syndromes. J Clin Densitom. 2013;16(1):69-74. doi: 10.1016/J.Jocd.2012.11.003.

5. Lassen T, Friis-Hansen L, Rasmussen AK, et al. Primary Hyperparathyroidism In Young People. When Should We Perform Genetic Testing For Multiple Endocrine Neoplasia 1 (Men-1)? J Clin Endocr Metab. 2014;99(11):3983-3987. doi: 10.1210/Jc.2013-4491.

6. Iacobone M, Carnaille B, Palazzo FF, Vriens M. Hereditary hyperparathyroidism-A consensus report of the European Society of Endocrine Surgeons (ESES). Langenbecks Arch Surg. 2015;400(8):867-886. doi: 10.1007/S00423-015-1342-7.

7. Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop. J Clin Endocrinol Metab. 2014;99(10):3580-3594. doi: 10.1210/Jc.2014-1415.

8. Wang K, Li M, Hakonarson H. Annovar: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38(16):E164. doi: 10.1093/Nar/Gkq603.

9. Мамедова Е.О., Пигарова Е.А., Мокрышева Н.Г., и др. Синдром множественных эндокринных неоплазий 1-го типа и семейный изолированный гиперпаратиреоз. // Клиническая Медицина. – 2015. – Т. 93. – №11 – С. 73-77. [Mamedova EO, Pigarova EA, Mokrysheva NG, et al. Type 1 multiple endocrine neoplasia syndrome and familial isolated hyperparathyroidism. Klinicheskaia Meditsina. 2015;93(11):73-77. (In Russ.).]

10. Mamedova E, Mokrysheva N, Kuznetsov S, et al. A novel Men1 polymorphism P.R176q in a young patient with primary hyperparathyroidism. In: Abstracts of the 14th International Workshop on multiple endocrine neoplasia and other rare endocrine tumors, September 25-27th, 2014, Vienna, Austria. Wien Klin Wochenschr. 2014;126(Suppl 3):139-170. doi: 10.1007/S00508-014-0578-5.

11. Мамедова Е.О., Мокрышева Н.Г., Пигарова Е.А., и др. Мутации в гене CDC73 у молодых пациентов с первичным гиперпаратиреозом (описание двух клинических случаев). // Терапевтический архив. – 2016. (в печати). [Mamedova EO, Mokrysheva NG, Pigarova EA, et al. CDC73 mutations in young patients with primary hyperparathyroidism (description of two clinical cases). Terapevticheskii arkhiv. Forthcoming 2016. (In Russ.)].

12. Skandarajah A, Barlier A, Morlet-Barlat N, et al. Should routine analysis of the Men1 gene be performed in all patients with primary hyperparathyroidism under 40 Years of age? World J Surg. 2010;34(6):1294-1298. doi: 10.1007/S00268-009-0388-5.

13. Langer P, Wild A, Hall A, et al. Prevalence of multiple endocrine neoplasia type 1 in young patients with apparently sporadic primary hyperparathyroidism or pancreaticoduodenal endocrine tumours. Br J Surg. 2003;90(12):1599-1603. doi: 10.1002/Bjs.4355.

14. Starker LF, Akerstrom T, Long WD, et al. Frequent germ-line mutations of the Men1, Casr, and Hrpt2/Cdc73 genes in young patients with clinically non-familial primary hyperparathyroidism. Horm Cancer. 2012;3(1-2):44-51. doi: 10.1007/S12672-011-0100-8.

15. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011. doi: 10.1210/Jc.2012-1230.

16. Jackson MA, Rich TA, Hu MI, et al. CDC73-related disorders. 2008 Dec 31 [Updated 2015 Jan 15]. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. Genereviews [Internet]. Seattle (WA): University Of Washington, Seattle; 1993-2016. Available From: Http://Www.Ncbi.Nlm.Nih.Gov/Books/NBK3789/

17. Singh Ospina N, Sebo TJ, Thompson GB, et al. Prevalence of parathyroid carcinoma in 348 patients with multiple endocrine neoplasia type 1 — case report and review of the literature. Clin Endocrinol (Oxf). 2016;84(2):244-249. doi: 10.1111/Cen.12714.

18. Scillitani A, Salcuni AS, Clemente C, et al. A rare case of multiple malignant parathyroid tumors in an atypical MEN1 family with a p.D418N mutation. In: Niederle B, Scheuba C, Bichler C, et al., Editors. 14th International workshop on multiple endocrine neoplasia and other rare endocrine tumors. Wiener Klinische Wochenschrift. 2014;126(S3):139-170. doi: 10.1007/S00508-014-0578-5.

19. Bassett JHD, Forbes SA, Pannett AAJ, et al. Characterization Of Mutations In Patients With Multiple Endocrine Neoplasia Type 1. Am J Hum Genet. 1998;62(2):232-244. doi: 10.1086/301729.

20. Simonds WF. Familial isolated hyperparathyroidism. Clinical Cases In Mineral And Bone Metabolism. 2006;3(2):175-183.

21. Elston MS, Meyer-Rochow GY, Dray M, et al. Early Onset Primary Hyperparathyroidism Associated With A Novel Germline Mutation In CDKN1B. Case Rep Endocrinol. 2015;2015:510985. doi: 10.1155/2015/510985.

22. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009;94(5):1826-1834. doi: 10.1210/Jc.2008-2083.

23. Costa-Guda J, Soong CP, Parekh VI, et al. Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas. Horm Cancer. 2013;4(5):301-307. doi: 10.1007/S12672-013-0147-9.